Maple syrup urine disease

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Maple syrup urine disease
L-isoleucine-skeletal.svg
Isoleucine (pictured above), leucine, and valine are the branched-chain amino acids that build up in MSUD.
Classification and external resources
ICD-10 E71.0
ICD-9 270.3
OMIM 248600
DiseasesDB 7820
MedlinePlus 000373
eMedicine ped/1368
Patient UK Maple syrup urine disease
MeSH D008375

Maple syrup urine disease (MSUD), also called branched-chain ketoaciduria, is an autosomal recessive[1] metabolic disorder affecting branched-chain amino acids. It is one type of organic acidemia.[2] The condition gets its name from the distinctive sweet odor of affected infants' urine, particularly prior to diagnosis, and during times of acute illness.[3]

Causes[edit]

MSUD is a metabolic disorder caused by a deficiency of the branched-chain alpha-keto acid dehydrogenase complex (BCKDC), leading to a buildup of the branched-chain amino acids (leucine, isoleucine, and valine) and their toxic by-products (ketoacids) in the blood and urine. The enzyme complex consists of four subunits designated E1α, E1β, E2, and E3. The E3 subunit is also a component of pyruvate dehydrogenase complex and oxoglutarate dehydrogenase complex.[4] MSUD can result from mutations in any of the genes that code for the enzyme subunits.

Diagnosis and symptoms[edit]

The disease is named for the presence of sweet-smelling urine, with an odor similar to that of maple syrup, when the patient goes into metabolic crisis. The smell is also present and sometimes stronger in the ear wax of an affected individual at these times. Prior to the easy availability of plasma amino acid measurement, diagnosis was commonly made based on suggestive symptoms and odor. Affected individuals are now often identified with characteristic elevations on plasma amino acids which do not have the characteristic odor.[5] The compound responsible for the odor is sotolon (sometimes spelled sotolone).[6] Infants with this disease seem healthy at birth but quickly deteriorate, often suffering severe brain damage, which may be permanent. Without prompt treatment they will die from cerebral oedema.

Untreated, and during times of metabolic crisis, symptoms of the condition include anorexia, vomiting, dehydration, lethargy, hypotonia, seizures, hypoglycaemia, ketoacidosis, opisthotonus, pancreatitis, rapid neurological decline, coma and cerebral oedema.

Classification[edit]

Maple syrup urine disease can be classified by its pattern of signs and symptoms, or by its genetic cause. The most common and severe form of the disease is the classic type, which appears soon after birth, and as long as it remains untreated, gives rise to progressive and unremitting symptoms. Variant forms of the disorder may appear later in infancy or childhood, with typically less severe symptoms that may only appear during times of fasting, stress or illness, but still involve mental and physical problems if left untreated.

There are several variations of the disease:

  • Classic Severe MSUD
  • Intermediate MSUD
  • Intermittent MSUD
  • Thiamine-responsive MSUD
  • E3-Deficient MSUD with Lactic Acidosis

Management[edit]

Keeping MSUD under control requires careful monitoring of blood chemistry, both at home and in a hospital setting. DNPH or specialised dipsticks are used to test the patient's urine for ketones (a sign of metabolic decompensation), when metabolic stress is likely or suspected. Fingerstick tests are performed regularly and sent to a laboratory to determine blood levels of leucine, isoleucine and valine. Regular metabolic consultations, including blood-draws for full nutritional analysis, are recommended; especially during puberty and periods of rapid growth. MSUD management also involves a specially tailored metabolic formula, a modified diet, and lifestyle precautions such as avoiding fatigue and infections, as well as consuming regular, sufficient calories in proportion to physical stress and exhertion. Without sufficient calories, catabolism of muscle protein will result in metabolic crisis. Those with MSUD must be hospitalised for intravenous infusion of sugars and nasogastric drip-feeding of formula, in the event of metabolic decompensation, or anorexia, diarrhoea or vomiting. Food avoidance, rejection of formula and picky eating are all common problems with MSUD. Some patients may need to receive all or part of their daily nutrition through a feeding tube.

A diet with carefully controlled levels of the amino acids leucine, isoleucine, and valine must be maintained at all times in order to prevent neurological damage. Since these three amino acids occur in all natural protein, and most natural foods contain some protein, any food intake must be closely monitored, and day-to-day protein intake calculated on a cumulative basis, to ensure individual tolerance levels are not exceeded at any time. As the MSUD diet is so protein-restricted, and adequate protein is a requirement for all humans, tailored metabolic formula containing all the other essential amino acids, as well as any vitamins, minerals, omega 3 fats and trace elements (which may be lacking due to the limited range of permissible foods), are an essential aspect of MSUD management. These complement the MSUD patient's natural food intake to meet normal nutritional requirements without causing harm.[7] If adequate calories cannot be obtained from natural food without exceeding protein tolerance, specialised low protein products such as starch-based baking mixtures, imitation rice and pasta may be prescribed, often alongside a protein-free carbohydrate powder added to food and/or drink, and increased at times of metabolic stress. Some patients with MSUD may also improve with administration of high doses of thiamine, a cofactor of the enzyme that causes the condition.

Usually, MSUD patients are monitored by a dietitian. The MSUD diet must be adhered to strictly and permanently. However, with proper management, those afflicted are able to live healthy, normal lives without suffering the severe neurological damage associated with the disease.

Genetic prevalence[edit]

Maple syrup urine disease has an autosomal recessive pattern of inheritance.

Maple syrup urine disease affects approximately 1 out of 185,000 infants.[8] Due in part to the founder effect,[9] however, MSUD has a much higher prevalence in children of Amish, Mennonite, and Jewish descent.[10][8][11]

Mutations in the following genes cause maple syrup urine disease:

These four genes produce proteins that work together as the branched-chain alpha-keto acid dehydrogenase complex. The complex is essential for breaking down the amino acids leucine, isoleucine, and valine. These are present in some quantity in almost all kinds of food, but in particular, protein-rich foods such as dairy products, meat, soy, gluten, eggs, nuts, whole grains, seeds, avocadoes, algae, edible seaweed, beans and pulses. Mutations in any of these genes reduces or eliminates the function of the enzyme complex, preventing the normal breakdown of isoleucine, leucine, and valine. As a result, these amino acids and their by-products build up in the body. Because high levels of these substances are toxic to the brain and other organs, this accumulation leads to the serious medical problems associated with maple syrup urine disease.

This condition has an autosomal recessive inheritance pattern, which means the defective gene is located on an autosome, and two copies of the gene – one from each parent – must be inherited to be affected by the disorder. The parents of a child with an autosomal recessive disorder are carriers of one copy of the defective gene, but are usually not affected by the disorder.

Screening[edit]

On 9 May 2014, the UK National Screening Committee (UK NSC) announced its recommendation to screen every newborn baby in the UK for four further genetic disorders as part of its NHS Newborn Blood Spot Screening programme, including maple syrup urine disease.[12]

See also[edit]

References[edit]

  1. ^ Podebrad F, Heil M, Reichert S, Mosandl A, Sewell AC, Böhles H (April 1999). "4,5-dimethyl-3-hydroxy-25H-furanone (sotolone)--the odour of maple syrup urine disease". Journal of Inherited Metabolic Disease 22 (2): 107–114. doi:10.1023/A:1005433516026. PMID 10234605. 
  2. ^ Ogier de Baulny H, Saudubray JM (2002). "Branched-chain organic acidurias". Semin Neonatol. 7 (1): 65–74. doi:10.1053/siny.2001.0087. PMID 12069539. 
  3. ^ "Maple syrup urine disease". Genetics Home Reference. 4 May 2015. 
  4. ^ Pasquali, Marzia; Longo, Nicola (December 13, 2011). "58. Newborn screening and inborn errors of metabolism". In Burtis, Carl A.; Ashwood, Edward R.; Bruns, David E. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics (5th ed.). Elsevier Health Sciences. p. 2062. ISBN 978-1-4160-6164-9. 
  5. ^ "#248600 Maple Syrup Urine Disease; MSUD". Johns Hopkins University. Retrieved 2012-11-04. 
  6. ^ Strauss, Kevin A; Puffenberger, Erik G; Morton, D Holmes (January 30, 2006). "Maple Syrup Urine Disease". In Pagon, Roberta A; Bird, Thomas D; Dolan, Cynthia R; Stephens, Karen; Adam, Margaret P. GeneReviews™ [Internet]. University of Washington, Seattle (published December 15, 2009). PMID 20301495. Retrieved May 15, 2012{{inconsistent citations}} 
  7. ^ Hallam P, Lilburn M, Lee PJ (2005). "A new protein substitute for adolescents and adults with maple syrup urine disease (MSUD)". J. Inherit. Metab. Dis. 28 (5): 665–672. doi:10.1007/s10545-005-0061-6. PMID 16151896. 
  8. ^ a b Mary Kugler, R.N. "Maple Syrup Urine Disease". About.com Health. 
  9. ^ Jaworski MA, Severini A, Mansour G, Konrad HM, Slater J, Henning K, Schlaut J, Yoon JW, Pak CY, Maclaren N et al. (1989). "Genetic conditions among Canadian Mennonites: evidence for a founder effect among the old country (Chortitza) Mennonites". Clin Invest Med 12 (2): 127–141. PMID 2706837. 
  10. ^ Puffenberger EG (2003). "Genetic heritage of Old Order Mennonites in southeastern Pennsylvania". Am J Med Genet C Semin Med Genet 121 (1): 18–31. doi:10.1002/ajmg.c.20003. PMID 12888983. 
  11. ^ http://www.mazornet.com/genetics/MapleSyrup.htm
  12. ^ "New screening will protect babies from death and disability". screening.nhs.uk. 

External links[edit]